HIRO-CAPITAL
16.9.2021 11:09:10 CEST | Business Wire | Press release
An SPV formed by Westerly Winds and Hiro Capital has come together to invest in Elvie, the revolutionary health and lifestyle brand developing iconic products for women, as part of the Femtech firm’s $97M Series C funding round. The Westerly Winds-Hiro SVP aligns with both firms’ ESG focus on investing in impactful technologies.
Founded in 2013 by CEO Tania Boler, Elvie brings together a team of world-class engineers, designers and business minds to develop extraordinary products that improve women’s lives – revolutionizing categories which had been overlooked for many years, including breast pumps and pelvic floor health.
Elvie’s products include Elvie Trainer, an award-winning gamified Kegel trainer, and Elvie Pump, the world’s first silent wearable breast pump. Elvie is the number one retailer in its category in the US and UK, and is a leader in the emerging femtech category which is expected to be a $50 billion market by 2025.
Maria S. Eitel, Founder Nike Foundation, Girl Effect commented: “For literally all of history, women's unique health needs and wellness desires have been undervalued and ignored. The team at Elvie is breaking new ground and creating new markets. It is a win-win for customers, investors, and the world, all benefiting from empowered, healthy, strong women”.
Jean Campbell, British Fashion Model, added: “In investing in Elvie I am proud to support a company where women are solving female needs. I have friends who in using the products extol the virtues of the female influence!”
Edward Van Cutsem, Founding Partner of Westerly Winds said: “We see tremendous opportunity in bringing a female-centric approach to innovation and technology to address women’s health and wellness. Elvie’s track record is impressive and we’re excited to back Tania and the broader team in this exciting new chapter.”
Cherry Freeman, General Partner at Hiro Capital added: “We are delighted to be investing in Elvie in partnership with Westerly Winds, alongside BlackRock and BGF. Tania is an extraordinary, passionate entrepreneur who has built one of the world’s leading femtech innovators. Hiro invests in brilliant, ethical creators building the next generation of games, fitness technology and digital wellness – Tania’s vision is a perfect fit with our values as a fund.”
About Westerly Winds
Westerly Winds is a venture investor with the mission to address the challenges that many entrepreneurs face when building companies and specialised asset management businesses in their formative years. We back and invest in dynamic visionary founders and companies that have the potential to become an integral part of the ‘new economy’. https://www.westerly-winds.com/
About Hiro Capital
Hiro Capital is a London / Luxembourg technology Venture Capital fund which invests in UK, US and European innovators in Games, Metaverse Technology, Esports, Digital Sports and Connected Wellness. We invest both in front-end Content and Product creators and in deep tech Metaverse applications of Cloud, Mobile, Streaming, Big Data, AI, Wearables, AR and VR technologies. Our core belief is that Games, Esports, Digital Sports and Wellness will be a central pillar of Entertainment, Economic and Social Life in the mid 21st century. We invest in the innovators who are building that future. https://hiro.capital/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005380/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 13:13:00 CEST | Press release
Orascom and Muriya press ahead across Hawana Salalah, Jebel Sifah and the US$90M+ As Sodah Island, signalling long-term conviction in Oman’s future, in step with Vision 2040. Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 13:00:00 CEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom